Development code · Biologic
ACI-35
ACI-35 is a development code for JNJ-2056 (ACI-35.030), developed by Johnson & Johnson.
- Status
- Phase 2 for Alzheimer's disease
- Mechanism
- Tau (pT217) Agonist
- Developer
- Johnson & Johnson
Programs
- JNJ-2056 (ACI-35.030) for Alzheimer's diseasePhase 2Active
Also known as
- JNJ-2056
- ACI-35.030
- JNJ-64042056
- VAC20121